In the current era of explosive growth in biomedical technology, the pharmaceutical R&D industry is undergoing a paradigm shift from "broad-spectrum treatment" to "precision intervention." Taking cancer treatment as an example, traditional chemotherapy drugs, like a "carpet bomb," inevitably damage normal cells while killing cancer cells. However, the advent of immunotherapies such as PD-1 inhibitors, by activating the body's own immune system to precisely identify and attack tumor cells, has increased the five-year survival rate of non-small cell lung cancer patients by nearly 30%. This breakthrough in targeted therapy stems from a deep understanding of the molecular mechanisms of the disease—scientists discovered that the PD-L1 protein on the surface of tumor cells can evade immune surveillance, leading to the development of drugs that block this signaling pathway.

The maturity of gene editing technology has propelled precision medicine to new heights. CRISPR-Cas9 technology, acting like "molecular scissors," can precisely modify disease-causing genes. In 2023, the world's first in vivo CRISPR therapy, CTX001, was approved for the treatment of sickle cell anemia. By editing the BCL11A gene in the patient's hematopoietic stem cells, it reactivates the expression of fetal hemoglobin, freeing the patient from transfusion dependence. This research approach of "solving problems at the source of genes" is reshaping the treatment landscape for rare and hereditary diseases. Meanwhile, AI-driven drug development platforms, through deep learning of massive amounts of biomedical data, are compressing the traditional drug development cycle from an average of 12 years to 4-5 years. For example, AlphaFold2 has an accuracy rate exceeding 90% in predicting the three-dimensional structure of proteins, providing key target information for small molecule drug design.